BioSpace News Archive

Science Exchange announced today that Ron Fischer has joined the company’s management team as VP of Engineering.

Kindbody, a new women’s healthcare company is launching today in the Bay Area with its mobile fertility pop-up. Kindbody, led by former Founder/CEO of Progyny, Gina Bartasi, is building a national network of boutique women’s healthcare facilities through pop-up and brick-and-mortar locations, with technology and patient experience at its core.

Pittsylvania County, Virginia, represented by Sanford Heisler Sharp, LLP, Kaufman & Canoles, P.C., and The Cicala Law Firm PLLC today initiated legal action against opioid manufacturers, distributors, and pharmacy benefit managers (PBMs) for their role in creating the public health emergency caused by prescription opioids.

VRHealth, the healthcare technology company providing specialized virtual reality (VR) technology solutions and data analysis, today announced that they are working with Oculus to deliver their newest health and wellness solutions using Oculus products.

Technavio has announced their latest drug pipeline analysis report on deep vein thrombosis. The report includes a comprehensive research on the pipeline molecules under investigation by the pharmaceutical companies within the defined data collection period for the treatment of deep vein thrombosis.

Aldeyra Therapeutics Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that it intends to offer and sell, subject to market and other conditions, 5,250,000 shares of its common stock in an underwritten public offering.

Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that the Company will present at the Cantor Fitzgerald 2018 Global Healthcare Conference on Tuesday, October 2

Vanda Pharmaceuticals, Inc.(Vanda) (Nasdaq: VNDA) today announced that it will participate at the following upcoming 2018 investor conferences:

Research shows adding Abbott’s High Sensitive Troponin-I diagnostic test to doctors’ existing standard of care can help more accurately determine a person’s chances of a heart attack or other cardiac event potentially months to years in advance

Upon the passage of the fiscal year (FY) 2019 Healthy and Human Services (HHS) budget with an additional $425 million designated for Alzheimer’s disease research—bringing the federal funding to fight Alzheimer’s to a total of $2.34 billion—The Alzheimer’s Foundation of America (AFA) issued the following statement from Charles J. Fuschillo, Jr., AFA’s president and CEO